arrow
M

Megumi Kai

the university of texas-md anderson cancer center
H指数:8
被引数:172

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer

新辅助派姆单抗联合化疗治疗非转移性三阴性炎性乳腺癌的病理完全缓解

2026-01-190
OAAI
Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition

回顾性分析显示,激素受体阳性转移性炎性乳腺癌患者对细胞周期依赖性激酶4/6抑制剂的应答不佳。

2025-12-100
OAAI
Forensic implications of ethyl glucuronide and ethyl sulfate pharmacokinetics in Japanese adults: the influence of dose, genetic polymorphisms, and habitual alcohol consumption

乙基葡萄糖苷和乙基硫酸盐药代动力学在成人中的法医学意义:剂量、基因多态性及习惯性酒精摄入的影响

2025-11-270
PRE
A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

一项Ib/II期临床试验,研究在HER2阳性或HR阳性/HER2阴性炎性乳腺癌患者(包括III期和IV期疾病)中,将奈拉替尼加入标准疗法的新辅助治疗。

2025-10-140
OA
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study

新辅助HER2靶向方案联合或未联合蒽环类药物用于HER2阳性炎性乳腺癌:一项多中心回顾性研究

2025-08-020
PRE
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

开发一个多机构数据集以验证一种新型炎性乳腺癌诊断评分

2025-03-310
PRE
Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
2024-05-020
PRE
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study
2024-05-020
PRE
Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system
2024-05-020
PRE
Phase II study of Pembrolizumab Maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy
2023-03-012
PRE
A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2+primary inflammatory breast cancer (IBC), and neratinib with taxol followed by AC in HR+/HER2-IBC
2023-03-010
PRE